Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)

Author's Avatar
Jun 12, 2023

Spruce+Biosciences%2C+Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for the 105%3Csup%3Eth%3C%2Fsup%3E+Annual+Meeting+of+the+Endocrine+Society+%28ENDO+2023%29 taking place June 15-18, 2023, in Chicago. In a poster presentation, the company will highlight the effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic congenital adrenal hyperplasia (CAH).